Indication
For the treatment of adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.
Medicine details
- Medicine name:
- guselkumab (Tremfya)
- SMC ID:
- SMC2850
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Publication due date:
- 10 November 2025